Endonovo Therapeutics Awarded Preliminary Injunction Against Kodiak Capital et 
Company Seeks a Permanent Injunction Against Sale, Lending,
Hypothecating or Transfer of Freely-Traded Unpaid for Shares
LOS ANGELES, CA -- (Marketwired) -- 06/23/16 --  Endonovo
Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a
developer of bioelectronic medicine and therapies, announced it has
been awarded a preliminary injunction by the Superior Court of
California, County of Los Angeles, against Kodiak Capital, BMA
Securities and COR Clearing, preventing the aforementioned parties
from selling, transferring, hypothecating or otherwise touching or
disposing of unpaid for shares tendered under the Equity Purchase
Agreement (the "EPA") with Kodiak Capital. The preliminary injunction
affirms a previously granted temporary restraining order placed on
over 1.89 million shares of freely traded shares of common stock.
"We now have a preliminary injunction preventing the possible use of
these unpaid for shares manipulating the market for our common
stock," stated Endonovo Chairman and CEO, Alan Collier. "We intend to
continue pursuing our rights through this lawsuit to protect our
shareholders' value. We have brought this lawsuit to seek the
cancellation or return of these unpaid shares to the Company and for
other damages. We believe that success in these efforts will increase
the likelihood of securing a larger round of financing and ensure a
transparent market for our common stock thus preserving shareholder
Mr. Collier went on to say, "The Company intends to learn if these
unpaid shares were utilized to manipulate the market price of our
stock. Further, we plan to judiciously pursue our legal remedies to
ensure our shareholders do not incur any damages and our stock price
returns to appropriate levels."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is an innovative biotechnology company
developing bioelectronic devices and therapies for regenerative
medicine. Endonovo's Immunotronics(TM) platform is a non-invasive,
non-implantable bioelectronic device for treating/preventing vital
organ failure through the reduction of inflammation, cell death and
the promotion of regeneration. Endonovo's Cytotronics(TM) platform
provides for a method of expanding and manipulating cells using
simulated microgravity and Time-Varying Electromagnetic Fields
(TVEMF) for tissue engineering and cell therapies. The Company's
initial concentration is on the treatment of acute and chronic
inflammatory conditions of the liver using its proprietary
Immunotronics(TM) platform.
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained in
this press release including words such as "anticipate," "believe,"
"plan," "estimate," "expect," "intend," and other similar expressions
of opinion, constitute forward-looking statements. Any such
forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from any future results
described within the forward-looking statements. Risk factors that
could contribute to such differences include those matters more fully
disclosed in the Company's reports filed with the Securities and
Exchange Commission. The forward-looking information provided herein
represents the Company's estimates as of the date of the press
release, and subsequent events and developments may cause the
Company's estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied upon
as representing the Company's estimates of its future financial
performance as of any date subsequent to the date of this press
Investors: Sign Up for Email Alerts on Endonovo 
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108